Abstract：
OBJECTIVE: Coronary heart disease (CHD) patients with changed serum soluble receptor for advanced glycation end products (sRAGE) will experience microalbuminuria and even kidney dysfunction. However, the role of sRAGE for microalbuminuria in CHD is still not established. This study aimed to evaluate the association between sRAGE and early kidney dysfunction in CHD patients.
METHODS: In this cross-sectional study, sRAGE and urinary albumin-to-creatinine ratio (uACR) were measured in hospitalized CHD patients who have undergone coronary arteriography to evaluate the distinction and correlation between sRAGE and uACR.
RESULTS: There were 127 CHD patients (mean age: 63.06 ± 10.93 years, 93 males) in the study, whose sRAGE were 1.83 ± 0.64 μg/L. The sRAGE level was higher in kidney injury group (uACR ≥ 30 mg/g) compared with no kidney injury group (uACR < 30 mg/g) [(2.08 ± 0.70 vs. 1.75 ± 0.61) μg/L, P < 0.05]. Moreover, the positive correlation between serum sRAGE and uACR was significant in CHD patients (r = 0.196, P < 0.05). Binary logistic regression suggests sRAGE as a predictor for microalbuminuria in CHD patients [Odd Ratio = 2.62 (1.12-6.15), P < 0.05)]. The area under the receiver operating characteristic curve (AUC) of sRAGE is higher than that of the traditional indicators of renal function such as creatinine and estimated glomerular filtration rate, indicating sRAGE might have a good performance in evaluating early kidney injury in CHD patients [AUC is 0.660 (0.543-0.778), P < 0.01)].
CONCLUSIONS: Serum sRAGE was positively correlated to uACR and might serve as a potential marker to predict early kidney injury in CHD patients.
METHODS: In this cross-sectional study, sRAGE and urinary albumin-to-creatinine ratio (uACR) were measured in hospitalized CHD patients who have undergone coronary arteriography to evaluate the distinction and correlation between sRAGE and uACR.
RESULTS: There were 127 CHD patients (mean age: 63.06 ± 10.93 years, 93 males) in the study, whose sRAGE were 1.83 ± 0.64 μg/L. The sRAGE level was higher in kidney injury group (uACR ≥ 30 mg/g) compared with no kidney injury group (uACR < 30 mg/g) [(2.08 ± 0.70 vs. 1.75 ± 0.61) μg/L, P < 0.05]. Moreover, the positive correlation between serum sRAGE and uACR was significant in CHD patients (r = 0.196, P < 0.05). Binary logistic regression suggests sRAGE as a predictor for microalbuminuria in CHD patients [Odd Ratio = 2.62 (1.12-6.15), P < 0.05)]. The area under the receiver operating characteristic curve (AUC) of sRAGE is higher than that of the traditional indicators of renal function such as creatinine and estimated glomerular filtration rate, indicating sRAGE might have a good performance in evaluating early kidney injury in CHD patients [AUC is 0.660 (0.543-0.778), P < 0.01)].
CONCLUSIONS: Serum sRAGE was positively correlated to uACR and might serve as a potential marker to predict early kidney injury in CHD patients.
摘要：
目的：冠心病（CHD）患者血清可溶性糖基化终末产物受体（sRAGE）改变后，会出现微量白蛋白尿甚至肾功能损害。然而,sRAGE对冠心病微量白蛋白尿的作用尚不明确.本研究旨在评估sRAGE与CHD患者早期肾功能障碍之间的关系。
方法：在这项横断面研究中，在接受冠状动脉造影的住院冠心病患者中测量sRAGE和尿白蛋白-肌酐比值（uACR），以评估sRAGE和uACR之间的区别和相关性。
结果：有127例冠心病患者（平均年龄：63.06±10.93岁，93名男性)在研究中，sRAGE为1.83±0.64μg/L。肾损伤组（uACR≥30mg/g）的sRAGE水平高于无肾损伤组（uACR<30mg/g）[（2.08±0.70vs.1.75±0.61)μg/L,P<0.05]。此外，冠心病患者血清sRAGE与uACR呈正相关(r=0.196,P<0.05)。二元logistic回归表明sRAGE是冠心病患者微量白蛋白尿的预测因子[奇数比=2.62(1.12-6.15),P<0.05)]。sRAGE的受试者工作特征曲线下面积(AUC)高于传统的肾功能指标如肌酐和估计的肾小球滤过率,表明sRAGE在评估冠心病患者的早期肾损伤方面可能具有良好的性能[AUC为0.660（0.543-0.778），P<0.01)]。
结论：血清sRAGE与uACR呈正相关，可作为预测冠心病患者早期肾损伤的潜在指标。
方法：在这项横断面研究中，在接受冠状动脉造影的住院冠心病患者中测量sRAGE和尿白蛋白-肌酐比值（uACR），以评估sRAGE和uACR之间的区别和相关性。
结果：有127例冠心病患者（平均年龄：63.06±10.93岁，93名男性)在研究中，sRAGE为1.83±0.64μg/L。肾损伤组（uACR≥30mg/g）的sRAGE水平高于无肾损伤组（uACR<30mg/g）[（2.08±0.70vs.1.75±0.61)μg/L,P<0.05]。此外，冠心病患者血清sRAGE与uACR呈正相关(r=0.196,P<0.05)。二元logistic回归表明sRAGE是冠心病患者微量白蛋白尿的预测因子[奇数比=2.62(1.12-6.15),P<0.05)]。sRAGE的受试者工作特征曲线下面积(AUC)高于传统的肾功能指标如肌酐和估计的肾小球滤过率,表明sRAGE在评估冠心病患者的早期肾损伤方面可能具有良好的性能[AUC为0.660（0.543-0.778），P<0.01)]。
结论：血清sRAGE与uACR呈正相关，可作为预测冠心病患者早期肾损伤的潜在指标。
